|
Giuseppe Derosa describes for SIIC the most significant aspects of his article describe para SIIC los aspectos relevantes de su artículo Sitagliptin vs glibenclamide SITAGLIPTIN OR GLIBENCLAMIDE IN ADDITION TO METFORMIN+PIOGLITAZONE? When metformin and pioglitazone combination is not enough to maintain an adequate glycemic control, sitagliptin should be preferred to glibenclamide as addition to the already ongoing therapy, for its better protection of beta-cell secretion, and its neutral effect on body weight. The article was published by El artículo fue publicado por
Principal institution where the research took place Institución principal de la investigación Department of Internal Medicine and Therapeutics, University of Pavia, PAVIA, Italy, Pavia, Italy, Italy  Authors' Report Crónica del Autor Bibliographic references Referencias bibliográficas Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1):193-203, 2009. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9(2):194-205, 2007. Weir GC, Leahy JL. Pathogenesis of non-insulin-dependent (type II) diabetes mellitus. In Joslin's diabetes mellitus. 13th edition. CR Kahn and GE Weir (eds.) Lea & Febiger. Philadelphia, PA; 1994. Pp. 240-264. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104(6):787-794, 1999. Williams-Herman D, Xu L, Teng R, Golm GT, Johnson J, Davies MJ, et al. Effect of initial combination therapy with sitagliptin and metformin on beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 14(1):67-76, 2012. Other articles written by the author Giuseppe Derosa Otros artículos de Giuseppe Derosa Derosa G, Maffioli P. Peroxisome proliferator-activated receptor-γ (Ppar-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 2012; 5(2): 272-281. Derosa G. Pioglitazone is a valid alternative to rosiglitazone. Am J Cardiovasc Drugs 2011; 11(6): 357-362. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010; 70(15): 1945-1961. Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009; 11(12): 1091-1099. Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin 2009; 25(3): 607-615. Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF, Maffioli P. Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. Diabetes Technol Ther 2012; 14(6):475-484. Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P. Exenatide plus metformin compared to metformin alone on β-cell function in patients with type 2 diabetes. Diabet Med; 29(12): 1515-1523. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism 2009; 58(8): 1059-1066. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J 2007; 37(2): 79-86. Derosa G, Cicero AF, Fogari E, D'Angelo A, Bianchi L, Maffioli P. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Horm Metab Res 2011; 43(7): 505-512. SIIC System of Assisted Editing (SSEA) / Sistema SIIC de Edición Asistida (SSEA)
The article is strictly related to the following sections of siicsalud El artículo se relaciona estrictamente con las siguientes secciones de siicsalud
Information about the full text Acerca del trabajo completo A Comparison Between Sitagliptin or Glibenclamide in Addition to Metformin + Pioglitazone on Glycaemic Control and Beta-Cell Function: The Triple Oral Therapy Author / Autor Giuseppe Derosa1, Arrigo Cicero2, Ivano Franzetti3, Fabrizio Querci4, Anna Carbone5, Mario Piccinni6, Angela D'angelo7, Elena Fogari8, Pamela Maffioli9 9 Md, Department Of Internal Medicine And Therapeutics, University Of Pavia, Pavia, Italy Access to the original source Diabetic Medicine Article URL: / URL del artículo: http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1464-5491 URL of Abstract: / URL del abstract: http://onlinelibrary.wiley.com/doi/10.1111/dme.12158/abstract URL of Abstract page in Medline: / URL del abstract en Medline: http://www.ncbi.nlm.nih.gov/pubmed/23413771 URL of Abstract page in Scopus: / URL del abstract en Scopus: http://2-s2.0-84879592855 siic DB: / siic DB: http://www.siicsalud.com/main/distriprinrel.php |
||||||||||||||||||||||
Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008
